CALL/VERTEX PHARMACEUTICALS/600/0.1/20.09.24 | Real-time BOERSE MUENCHEN 19:26:46 28/05/2024 BST | ||
| 0.136 EUR | +6.25% |
|
| Current month | +40.66% | ||
| 1 month | +82.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 0.136 | +6.25% |
| 27/05/24 | 0.128 | +10.34% |
| 24/05/24 | 0.116 | +17.17% |
| 23/05/24 | 0.099 | +11.24% |
| 22/05/24 | 0.089 | -7.29% |
Real-time BOERSE MUENCHEN
Last update May 28, 2024 at 07:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG2S51 |
| ISIN | DE000GG2S518 |
| Date issued | 18/01/2024 |
| Strike | 600 $ |
| Maturity | 20/09/2024 (115 Days) |
| Parity | 10 : 1 |
| Emission price | 0.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.571 € |
|---|---|
| Lowest since issue | 0.041 € |
| Spread | 0.25 € |
| Spread % | 71.43% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Warrants
- Warrant
